National Institute of Health (NIH) has started the local manufacturing of CanSinoBIO’s COVID-19 vaccine after importing the raw material from China.
According to a statement by NIH, the raw material imported from the neighboring country is sufficient to produce 120,000 doses, which will be available for use by the end of May.
NIH researchers are working along with Chinese scientists for the manufacturing of CanSinoBIO’s COVID-19 vaccine.
Last month, NIH had announced plans to start local production of CanSinoBIO’s vaccine in May.
